Patent Assignment
Reel/Frame 050044/0181
Security Interest
Recorded: 2019-08-13
Pages: 38
Assignee
MIDCAP FINANCIAL TRUST, AS AGENT
7255 WOODMONT AVE., SUITE 200, BETHESDA, MARYLAND, 20814
Covered Properties
(215)
Diketopiperazine Salts for Drug Delivery and Related Methods
Catalysis of Diketopiperazine Synthesis
Superior Control of Blood Glucose in Diabetes Treatment
Application:
15/377,641 →
Publication:
US US20170087217A1
Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents
Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent
Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent
Application:
16/453,875 →
Publication:
US US20190314276A1
Dry Powder Inhalation System
Application:
14/863,136 →
Publication:
US US20160008557A1
Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces
Method of Preventing Adverse Effects by Glp-1
Application:
13/732,911 →
Publication:
US US20130125886A1
Method of Treating Diabetes Type 2 by Administering Ultrarapid Acting Insulin
Dry Powder Inhaler and System for Drug Delivery
Dry Powder Inhaler and System for Drug Delivery
Interactive Apparatus and Method for Real-Time Profiling of Inhalation Efforts
Use of Ultrarapid Acting Insulin
Use of Ultrarapid Acting Insulin
Delivery of Active Agents
Application:
13/737,823 →
Publication:
US US20130118491A1
Delivery of Active Agents
Application:
16/267,231 →
Publication:
US US20190167580A1
Dry Powder Inhaler and System for Drug Delivery
Diketopiperazine Microparticles with Defined Specific Surface Areas
Dry Powder Drug Delivery System
Application:
16/410,191 →
Publication:
US US20190262557A1
Method for Treating Hyperglycemia with Glp-1
Application:
15/640,835 →
Publication:
US US20170304404A1
Method and Composition for Administering Prostaglandins
Application:
15/445,539 →
Publication:
US US20170232001A1
Blister Package for Pharmaceutical Cartridges
High Capacity Diketopiperazine Microparticles and Methods
High Capacity Diketopiperazine Microparticles and Methods
Dry Powder Drug Delivery System and Methods
Microcrystalline Diketopiperazine Compositions and Methods
Insufflation Apparatus and Methods
Heat-Stable Dry Powder Pharmaceutical Compositions and Methods
Heat-Stable Dry Powder Pharmaceutical Compositions and Methods
Mouthpiece Cover for an Inhaler
Dry Powder Inhaler
Application:
15/418,388 →
Publication:
US US20170216538A1
Apparatus, System and Method for Detecting and Monitoring Inhalations
Composition and Method for Reducing Hypoglycemia Events in Diabetes Treatment
Inhalable Dry Powders
Application:
62/822,303 →
Formation of N-Protected 3,6-Bis-(4-Aminoalkyl)-2,5,Diketopiperazine
Methods for the synthesis of activated ethylfumarates and their use as intermediates
Formation of N-Protected 3,6-Bis-(4-Aminobutyl)-2,5-Diketopiperazine Through a Cyclic Alpha-N-Protected Amino Ester Intermediate
Powder Dispensing and Sensing Apparatus and Methods for Simultaneous Filling of Cartridges
Reactor for Producing Pharmaceutical Particles in a Precipitation Process
Apparatus and Method for Cryogranulating a Pharmaceutical Composition
Diketopiperazine Salts for Drug Delivery and Related Methods
Diketopiperazine Salts for Drug Delivery and Related Methods
Diketopiperazine Salts for Drug Delivery and Related Methods
Diketopiperazine salts for drug delivery and related methods
Diketopiperazine salts for drug delivery and related methods
Diketopiperazine Salts for Drug Delivery and Related Methods
Catalysis of Diketopiperazine Synthesis
Catalysis of Diketopiperazine Synthesis
Catalysis of Diketopiperazine Synthesis
Catalysis of Diketopiperazine Synthesis
Catalysis of Diketopiperazine Synthesis
Catalysis of Diketopiperazine Synthesis
Potentiation of glucose elimination
Potentiation of Glucose Elimination
Superior Control of Blood Glucose in Diabetes Treatment
Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents
Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents
Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents
Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents
Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents
Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent
Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent
Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent
Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent
Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces
Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces
Increasing Drug Affinity for Crystalline Microparticle Surfaces
Method of Drug Formulation
Substituted Diketopiperazine Analogs for Use as Drug Delivery Agents
Substituted Diketopiperazine Analogs for Use as Drug Delivery Agents
Substituted Diketopiperazine Analogs for Use as Drug Delivery Agents
Substituted Diketopiperazine Analogs for Use as Drug Delivery Agents
Substituted Diketopiperazine Analogs for Use as Drug Delivery Agents
Method of Preventing Adverse Effects by Glp-1
Dry Powder Formulations of Antihistamine for Nasal Administration
Dry Powder Formulations of Antihistamine for Nasal Administration
Purification and Stabilization of Peptide and Protein Pharmaceutical Agents
Patent:
6,444,226 →
Application:
09/606,468 →
Purification and Stabilization of Peptide and Protein Pharmaceutical Agents
A Method for Delivery of Monomeric or Dimeric Insulin Complexed to Diketopiperazine Microparticles
Methods and Compositions for Delivering Peptides
Methods and Compositions for Delivering Peptides
Methods and Compositions for Delivering Peptides
Unit Dose Capsules for Use in a Dry Powder Inhaler
Patent:
7,305,986 →
Application:
09/621,092 →
Unit Dose Capsules and Dry Powder Inhaler
Unit Dose Capsules and Dry Powder Inhaler
Unit Dose Capsules and Dry Powder Inhaler
Unit Dose Capsules and Dry Powder Inhaler
Inhalation Apparatus
Inhalation Apparatus
Inhalation Apparatus
Inhalation Apparatus
Inhalation Apparatus
Methods for Fine Powder Formation
Patent:
6,440,463 →
Application:
09/543,309 →
Methods for Fine Powder Formation
Unit Dose Cartridge and Dry Powder Inhaler
Unit Dose Cartridge and Dry Powder Inhaler
Unit Dose Cartridge and Dry Powder Inhaler
Compositions for Treatment or Prevention of Bioterrorism
A Method of Treating Diabetes Type 2 by Metformin and an Ultrarapid Acting Insulin
A Method of Treating Diabetes Type 2 by Administering Ultrarapid Acting Insulin
Use of Ultrarapid Acting Insulin
Dry Powder Inhaler and System for Drug Delivery
Dry Powder Inhaler and System for Drug Delivery
Interactive Apparatus and Method for Real-Time Profiling of Inhalation Efforts
A Method of Controlling Glycemia by Ultrarapid Acting Insulin Without Adjusting an Insulin Dose for Meal Content
Use of Ultrarapid Acting Insulin
Use of Ultrarapid Acting Insulin
Use of Ultrarapid Acting Insulin
Delivery of Active Agents
Apparatus, System and Method for Measuring Resistance of an Inhaler
Apparatus, System and Method for Measuring Resistance of an Inhaler
Apparatus, System and Method for Measuring Resistance of an Inhaler
Inhaler Adaptor for a Laser Diffraction Apparatus and Method for Measuring Particle Size Distribution
Laser Diffraction with Inhaler Enclosed in Positive Pressure Chamber.
Laser Diffraction with Inhaler Enclosed in Positive Pressure Chamber
Dry Powder Inhaler and System for Drug Delivery
Dry Powder Inhaler and System for Drug Delivery
Diketopiperazine Microparticles with Defined Specific Surface Areas
Diketopiperazine Microparticles with Defined Specific Surface Areas
Diketopiperazine Microparticles with Defined Specific Surface Areas
Diketopiperazine Microparticles with Defined Specific Surface Areas
Diketopiperazine Microparticles with Defined Isomer Contents
Dry Powder Inhaler and System for Drug Delivery
Dry Powder Inhaler and System for Drug Delivery
Dry Powder Inhaler and System for Drug Delivery
Dry Powder Inhaler and System for Drug Delivery
Dry Powder Inhaler and System for Drug Delivery
Dry powder drug delivery system
Dry Powder Drug Delivery System
Dry Powder Drug Delivery System
Val (8) GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome
Apparatus and Method for Simulating Inhalation Efforts
Apparatus and Method for Simulating Inhalation Efforts
Method for Treating Hyperglycemia
Method for Treating Hyperglycemia with GLP-1
Method of Drug Formulation of Compositions Comprising Crystalline Microparticle Surfaces
Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces
Dry Powder Drug Delivery System and Methods
Dry Powder Drug Delivery System and Methods
Method and Composition for Treating Migraines
Blister Package for Pharmaceutical Cartridges
High Capacity Diketopiperazine Microparticles and Methods
High Capacity Diketopiperazine Microparticles and Methods
Methods and Compositions for Treating Pain
Methods and Compositions for Treating Pain
Methods and Compositions for Reducing Opioid Side Effects
Dry Powder Drug Delivery System and Methods
Inhalable Vaccine Compositions and Methods
Heat-Stable Dry Powder Pharmaceutical Compositions and Methods
Formation of N-Protected bis-3,6-(4-aminoalkyl)-2,5,diketopiperazine
Formation of N-Protected bis-3,6-(4-aminoalkyl)-2,5,diketopiperazine
Formation of N-Protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine
Methods for the Synthesis of Activated Ethylfumarates and Their Use as Intermediates
Methods for the synthesis of activated ethylfumarates and their use as intermediates
Formation of N-Protected Bis-3,6-(4-Aminobutyl)-2,5-Diketopiperazine Through a Cyclic Alpha-N-Protected Amino Ester
Formation of N-Protected 3,6-Bis-(4-Aminobutyl) -2, 5-Diketopiperazine Through a Cyclic Alpha-N-Protected Active Amino Ester Intermediate
Formation of N-Protected Bis-3,6- (4-Aminobutyl) -2, 5-Diketopiperazine Through a Cyclic Alpha-N-Protected Amino Ester
Powder Dispensing and Sensing Apparatus and Methods
Powder Dispensing and Sensing Apparatus and Methods
Powder Dispensing and Sensing Apparatus and Methods
Powder Dispensing and Sensing Apparatus and Methods
Powder Dispenser Modules and Powder Dispensing Methods
Powder Dispenser Modules and Powder Dispensing Methods
Powder Transport Systems and Methods
Powder Transport Systems and Methods
Powder Feed System
Powder Dispenser Modules and Powder Dispenser Assemblies
Reactor for Producing Pharmaceutical Particles in a Precipitation Process
Apparatus and Method for Cryogranulating a Pharmaceutical Composition
Apparatus and Method for Cryogranulating a Pharmaceutical Composition
Apparatus and Method for Cryogranulating a Pharmaceutical Composition
Determining Percent Solids in Suspension Using Raman Spectroscopy
Determining Percent Solids in Suspension Using Raman Spectroscopy
Determining Percent Solids in Suspension Using Raman Spectroscopy
Multiple Kinase Pathway Inhibitors
Monoclonal Antibodies and Diagnostic Uses Thereof
Modulation of Allergic Response
Expression Vectors Encoding Epitopes of Target-Associated Antigens and Methods for Their Design
Methods and Compositions to Elicit Multivalent Immune Responses Against Dominant and Subdominant Epitopes, Expressed on Cancer Cells and Tumor Stroma
Multivalent Entrain-and-Amplify Immunotherapeutics for Carcinoma
Ssx-2 Peptide Analogs
Dry Powder Inhaler
Patent:
635,241 →
Application:
29/319,775 →
Dry Powder Inhaler
Patent:
604,833 →
Application:
29/319,778 →
Catridge for a Dry Powder Inhaler
Patent:
605,753 →
Application:
29/319,776 →
Dry Powder Inhaler
Patent:
597,657 →
Application:
29/319,777 →
Dry Powder Inhaler
Patent:
605,752 →
Application:
29/319,774 →
Cartridge for a Dry Powder Inhaler
Patent:
604,832 →
Application:
29/319,773 →
Dry Powder Inhaler
Patent:
629,887 →
Application:
29/328,739 →
Dry Powder Inhaler
Patent:
629,888 →
Application:
29/328,744 →
Dry Powder Inhaler
Patent:
629,886 →
Application:
29/328,724 →
Dry Powder Inhaler
Patent:
635,243 →
Application:
29/328,742 →
Dry Powder Inhaler
Patent:
629,506 →
Application:
29/328,733 →
Dry Powder Inhaler
Patent:
635,242 →
Application:
29/328,728 →
Dry Powder Inhaler
Patent:
629,505 →
Application:
29/328,731 →
Cartridge for a Dry Powder Inhaler
Patent:
613,849 →
Application:
29/333,230 →
Cartridge for a Dry Powder Inhaler
Patent:
664,640 →
Application:
29/356,555 →
Dry Powder Inhaler
Patent:
614,760 →
Application:
29/333,232 →
Dry Powder Inhaler
Patent:
636,868 →
Application:
29/363,773 →
Dry Powder Inhaler
Patent:
636,869 →
Application:
29/363,775 →
Dry Powder Inhaler
Patent:
636,867 →
Application:
29/363,768 →
Blister Packaging
Patent:
643,308 →
Application:
29/375,859 →
Blister Packaging
Patent:
671,842 →
Application:
29/394,877 →
Inhaler Device
Patent:
674,893 →
Application:
29/404,464 →
Mouthpiece Cover
Patent:
771,237 →
Application:
29/504,212 →
Mouthpiece Cover
Patent:
802,116 →
Application:
29/579,594 →
Inhaler
Patent:
824,015 →
Application:
29/553,303 →
Inhaler
Patent:
841,798 →
Application:
29/553,302 →
Inhaler
Patent:
824,016 →
Application:
29/553,305 →
Inhaler
Patent:
824,510 →
Application:
29/553,300 →
Inhaler
Patent:
834,178 →
Application:
29/604,731 →
Inhaler
Patent:
851,748 →
Application:
29/625,323 →
Apparatus, System and Method for Detecting and Monitoring Inhalations
PCT:
PCT/US2019/028986 ↗
Method and Composition for Treating Obesity
PCT:
PCT/US2019/029166 ↗
Composition and Method for Inhalation
PCT:
PCT/US2019/036095 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 4, 2013
From: RICHARDSON, PETER; BAUGHMAN, ROBERT A.; COSTELLO, DONALD
To: MANNKIND CORPORATION
Reel/Frame 029570/0900 →
Assignment of Assignor's Interest
Feb 14, 2013
From: RICHARDSON, PETER; BAUGHMAN, ROBERT A.; LEONE-BAY, ANDREA; COSTELLO, DONALD
To: MANNKIND CORPORATION
Reel/Frame 029814/0047 →
Security Agreement
Jul 3, 2013
From: MANNKIND CORPORATION
To: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
Reel/Frame 030740/0123 →
Patent Security Agreement
Sep 26, 2014
From: MANNKIND CORPORATION
To: AVENTISUB LLC
Reel/Frame 033831/0110 →
Assignment of Assignor's Interest
Oct 22, 2015
From: SMUTNEY, CHAD C.; KINSEY, P. SPENCER; POLIDORO, JOHN M.; SAHI, CARL R.
To: MANNKIND CORPORATION
Reel/Frame 036861/0106 →
Assignment of Assignor's Interest
Apr 14, 2016
From: SMUTNEY, CHAD C.; KINSEY, P. SPENCER; SAHI, CARL R.; ADAMO, BENOIT
To: MANNKIND CORPORATION
Reel/Frame 038282/0125 →
Assignment of Assignor's Interest
May 18, 2016
From: OVERFIELD, DENNIS; SAHI, CARL R.; ADAMO, BENOIT; KINSEY, P. SPENCER
To: MANNKIND CORPORATION
Reel/Frame 038637/0573 →
Release of Security Interest
Nov 10, 2016
From: AVENTISUB LLC
To: MANNKIND CORPORATION
Reel/Frame 040588/0008 →
Assignment of Assignor's Interest
Mar 31, 2017
From: FREEMAN, JOHN J., JR.
To: MANNKIND CORPORATION
Reel/Frame 041817/0088 →
Assignment of Assignor's Interest
Mar 31, 2017
From: GRANT, MARSHALL L.; STOWELL, GRAYSON W.; MENKIN, PAUL
To: MANNKIND CORPORATION
Reel/Frame 041816/0961 →
Assignment of Assignor's Interest
Apr 13, 2017
From: CHEATHAM, WAYMAN WENDELL; BOSS, ANDERS HASAGER
To: MANNKIND CORPORATION
Reel/Frame 042003/0975 →
Assignment of Assignor's Interest
Mar 30, 2018
From: RICHARDSON, PETER; BAUGHMAN, ROBERT A.; POTOCKA, ELIZABETH; BOSS, ANDERS HASAGER
To: MANNKIND CORPORATION
Reel/Frame 045399/0448 →
Assignment of Assignor's Interest
Oct 4, 2018
From: LEONE-BAY, ANDREA; MOYE-SHERMAN, DESTARDI; WILSON, BRYAN R.
To: MANNKIND CORPORATION
Reel/Frame 047070/0205 →
Assignment of Assignor's Interest
Oct 4, 2018
From: HOKENSON, MARK; OBERG, KEITH A.
To: MANNKIND CORPORATION
Reel/Frame 047070/0887 →
Assignment of Assignor's Interest
Oct 4, 2018
From: STEVENSON, JOHN J.; MOYE-SHERMAN, DESTARDI
To: MANNKIND CORPORATION
Reel/Frame 047069/0956 →
Assignment of Assignor's Interest
Oct 4, 2018
From: GRANT, MARSHALL; WILSON, BRYAN R.
To: MANNKIND CORPORATION
Reel/Frame 047070/0623 →
Assignment of Assignor's Interest
Oct 16, 2018
From: SMUTNEY, CHAD C.; KINSEY, P. SPENCER; SAHI, CARL R.; ADAMO, BENOIT
To: MANNKIND CORPORATION
Reel/Frame 047176/0330 →
Assignment of Assignor's Interest
Nov 8, 2018
From: BOSS, ANDERS HASAGER; PETRUCCI, RICHARD; HOWARD, CAMPBELL; MANN, ALFRED
To: MANNKIND CORPORATION
Reel/Frame 047455/0392 →
Assignment of Assignor's Interest
Feb 5, 2019
From: RICHARDSON, PETER; BAUGHMAN, ROBERT A.; LEONE-BAY, ANDREA; COSTELLO, DONALD
To: MANNKIND CORPORATION
Reel/Frame 048239/0075 →
Assignment of Assignor's Interest
Feb 14, 2019
From: SMUTNEY, CHAD C.; KINSEY, P. SPENCER; SAHI, CARL R.; ADAMO, BENOIT
To: MANNKIND CORPORATION
Reel/Frame 048339/0576 →
Assignment of Assignor's Interest
Aug 7, 2019
From: OBERG, KEITH A.; SULNER, JOSEPH; GRANT, MARSHALL L.
To: MANNKIND CORPORATION
Reel/Frame 049993/0593 →
Assignment of Assignor's Interest
Aug 8, 2019
From: BOSS, ANDERS HASAGER; PETRUCCI, RICHARD
To: MANNKIND CORPORATION
Reel/Frame 050006/0152 →
Release of Security Interest
Aug 13, 2019
From: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
To: MANNKIND CORPORATION
Reel/Frame 050044/0138 →
Assignment of Assignor's Interest
Mar 24, 2020
From: WILSON, BRYAN R.; GRANT, MARSHALL
To: MANNKIND CORPORATION
Reel/Frame 052212/0253 →
Release of Security Interest
Apr 5, 2024
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: MANNKIND CORPORATION; MANNKIND LLC
Reel/Frame 067024/0082 →